AstraZeneca PLC American Depositary Shares

Company Overview

Business Model: AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines. The Company's primary revenue generation mechanisms are product sales across various therapeutic areas, supplemented by alliance and collaboration revenues. Its portfolio includes medicines for oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, vaccines and immune therapies, and rare diseases.

Market Position: While specific market share data is not provided, AstraZeneca PLC maintains a significant global presence in the pharmaceutical industry, evidenced by its extensive product pipeline, broad geographic sales distribution, and strategic acquisitions of specialized businesses like MedImmune and Alexion. The Company's focus on innovative therapies across multiple disease areas positions it as a key player in the global biopharmaceutical landscape.

Recent Strategic Developments: AstraZeneca PLC has actively shaped its portfolio through strategic acquisitions and divestitures. Key developments include the acquisition of MedImmune in 2007 and Alexion in 2021, both US-based businesses, significantly expanding its rare disease capabilities. More recently, the Company acquired Gracell Biotechnologies Inc. in February 2024, enhancing its cell therapy pipeline, and Fusion Pharmaceuticals Inc. in June 2024, adding next-generation radioconjugates. In August 2025, AstraZeneca gained control of roxadustat rights and manufacturing in China through the acquisition of FibroGen China. The Company also acquired the remaining non-controlling interest in SixPeaks Bio AG in October 2025. In 2026, AstraZeneca PLC terminated its American Depositary Receipt (ADR) programme and directly listed all Ordinary Shares on the New York Stock Exchange, effective February 2, 2026.

Geographic Footprint: AstraZeneca PLC operates globally with a significant presence across major pharmaceutical markets. Its primary operational regions and key markets include the US, Europe (with notable contributions from the UK, Germany, and Sweden), Emerging Markets (with China being a substantial contributor), and Established Rest of World (ROW) markets, including Japan and Canada. The Company maintains a vast international presence through numerous wholly-owned subsidiaries and other holdings across Algeria, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Indonesia, Iran, Ireland, Israel, Italy, Japan, Kazakhstan, Kenya, Latvia, Lithuania, Luxembourg, Malaysia, Mexico, Morocco, The Netherlands, New Zealand, Nigeria, Norway, Pakistan, Panama, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Tunisia, Turkey, Ukraine, United Arab Emirates, United Kingdom, United States, Uruguay, Venezuela, and Vietnam.

Cross-Border Operations: AstraZeneca PLC's cross-border operations are extensive, supported by a network of wholly-owned subsidiaries and strategic partnerships globally. The Company has subsidiaries in over 70 countries, including significant R&D and manufacturing operations in China (e.g., AstraZeneca Global R&D (Beijing) Co., Ltd., AstraZeneca Pharmaceutical Manufacturing (Qingdao) Co., Ltd.) and the US (e.g., Alexion Pharmaceuticals, Inc., MedImmune, LLC). It also engages in joint ventures, such as IHP HK Holdings Limited (50%) and Montrose Chemical Corporation of California (50%), and holds significant associated holdings in various companies globally, including Dizal (Jiangsu) Pharmaceutical Co., Ltd. (23.71%) in China and Cellectis S.A. (43.85%) in France. The Company maintains a legal entity in Iran, AstraZeneca Pars Company, which facilitates product sales through a third-party distributor, generating gross revenues of $33 million and net profits of $19 million in 2025. None of AstraZeneca PLC's US entities are involved in business activities in Iran.

Financial Performance

Revenue Analysis

Profitability Metrics (2025):

• Gross Margin: 81.9%
• Operating Margin: 23.4%
• Net Margin: 17.4%

Investment in Growth:

• R&D Expenditure: $14.2 billion (24.2% of revenue)
• Capital Expenditures: Contracts placed for future capital expenditure amounted to $1.7 billion in 2025.
• Strategic Investments: Major investment initiatives include the acquisitions of Gracell Biotechnologies Inc. for $1.0 billion (primarily for AZD0120), Fusion Pharmaceuticals Inc. for $2.2 billion (for radioconjugates like FPI-2265), FibroGen China for $221 million (for roxadustat rights), and the remaining non-controlling interest in SixPeaks Bio AG for $248 million.

Currency Impact Analysis:

• Approximately 59% of AstraZeneca PLC's total revenue in 2025 was denominated in non-US dollar currencies, creating significant foreign exchange exposure.
• Manufacturing and R&D costs are primarily denominated in pound sterling and Swedish krona.
• The Company's functional currency is US dollars. Exchange gains and losses on loans and short-term foreign currency borrowings and deposits are included in Finance expense, while other foreign currency transaction differences are recognized in Operating profit.
• Hedging strategies include cross-currency swaps designated as net investment hedges, cash flow hedges, and fair value hedges, as well as forward foreign exchange contracts designated as cash flow hedges.
• A 10% strengthening of the US dollar would increase the fair value of financial instruments by $88 million, impact profit by $(13) million, and equity by $101 million. Conversely, a 10% weakening would decrease fair value by $(111) million, impact profit by $16 million, and equity by $(126) million.

Business Segment Analysis

The Group has one reportable segment: pharmaceuticals. The following analysis breaks down product sales by therapeutic area.

Oncology

Financial Performance (2025 Product Sales):

• Revenue: $24.9 billion (+17.6% YoY actual, +19.0% YoY constant currency)
• Key Growth Drivers: Strong performance across key products, particularly Imfinzi (+35% US, +34% Emerging Markets), Enhertu (+91% Emerging Markets, +64% Europe), and Truqap (+44% US, +445% Ex-US). Continued growth from Tagrisso and Calquence.

Product Portfolio:

• Major product lines include Tagrisso (osimertinib), Imfinzi (durvalumab), Calquence (acalabrutinib), Lynparza (olaparib), Enhertu (trastuzumab deruxtecan), Truqap (capivasertib), Imjudo (tremelimumab), and Datroway (datopotamab deruxtecan).
• New product launches or major updates: Datroway was launched in 2025 (Ex-US sales $2 million). The pipeline includes numerous candidates in Phase I, II, and III, such as camizestrant (ngSERD for breast cancer), saruparib (PARP1 inhibitor), sonesitatug vedotin (CLDN18.2 MMAE ADC), and volrustomig (PD-1/CTLA-4 bispecific mAb).

Market Dynamics:

• The oncology segment is highly competitive and innovation-driven. AstraZeneca PLC's strategy focuses on targeted therapies, immunotherapies, and antibody-drug conjugates (ADCs).
• Patent expiries for key products like Calquence (US 2026), Imfinzi (China/EU 2030, US 2031), and Tagrisso (US/China/EU 2032) are significant considerations.

Geographic Revenue Distribution (2025 Product Sales):

• US: $11.2 billion (45.0% of segment revenue)
• Emerging Markets: $5.4 billion (21.5% of segment revenue), with China contributing $2.0 billion.
• Europe: $4.9 billion (19.6% of segment revenue)
• Established ROW: $2.3 billion (9.2% of segment revenue), with Japan contributing $1.7 billion.

CVRM (Cardiovascular, Renal & Metabolism)

Financial Performance (2025 Product Sales):

• Revenue: $12.8 billion (+2.4% YoY actual, +4.0% YoY constant currency)
• Key Growth Drivers: Strong growth from Farxiga/Forxiga (+17% Emerging Markets, +12% Europe) and Lokelma (+18% US, +50% Emerging Markets, +39% Europe). Wainua, a new launch, showed significant growth (+139% US).
• Brilinta/Brilique experienced a significant decline (-48% US, -45% Europe) due to patent expiry.

Product Portfolio:

• Major product lines include Farxiga/Forxiga (dapagliflozin), Brilinta/Brilique (ticagrelor), Lokelma (sodium zirconium cyclosilicate), Roxadustat, and Wainua/Wainzua (eplontersen).
• New product launches or major updates: Wainua was launched in 2025 (US sales $204 million). The pipeline includes balcinrenone/dapagliflozin (for heart failure with CKD), baxdrostat (aldosterone synthase inhibitor for hypertension), and elecoglipron (oral GLP-1 receptor agonist for T2D/obesity).

Market Dynamics:

• The CVRM market is characterized by high prevalence of chronic diseases and increasing competition from generics, particularly for older products. Innovation in SGLT2 inhibitors (Farxiga) and new mechanisms for rare cardiovascular diseases (Wainua) are key drivers.
• Patent expiries for Brilinta/Brilique (US/EU 2025) and Farxiga/Forxiga (US 2026) are notable.

Geographic Revenue Distribution (2025 Product Sales):

• Emerging Markets: $5.9 billion (46.0% of segment revenue), with China contributing $3.3 billion.
• Europe: $3.4 billion (26.5% of segment revenue)
• US: $2.7 billion (21.2% of segment revenue)
• Established ROW: $0.8 billion (5.9% of segment revenue), with Japan contributing $0.6 billion.

Respiratory & Immunology

Financial Performance (2025 Product Sales):

• Revenue: $7.3 billion (+7.4% YoY actual, +8.0% YoY constant currency)
• Key Growth Drivers: Strong growth from Fasenra (+14% US, +27% Emerging Markets, +19% Europe), Saphnelo (+40% US, +89% Europe), Breztri/Trixeo (+19% US, +22% Emerging Markets, +33% Europe), and Tezspire (+90% Europe, +51% Established ROW). Symbicort and Pulmicort experienced declines in some markets.

Product Portfolio:

• Major product lines include Symbicort (budesonide/formoterol), Fasenra (benralizumab), Breztri/Trixeo Aerosphere (budesonide/glycopyrronium/formoterol), Saphnelo (anifrolumab), Tezspire (tezepelumab), Airsupra (albuterol/budesonide), and Pulmicort.
• New product launches or major updates: Airsupra was launched in 2025 (US sales $162 million). The pipeline includes tozorakimab (IL-33 mAb for COPD and severe viral lower respiratory tract disease) and atuliflapon (FLAP inhibitor for asthma).

Market Dynamics:

• The respiratory and immunology market is driven by biologics and triple therapies for severe asthma and COPD. Competition from biosimilars and generics impacts older products.
• Patent expiries for Symbicort (US 2025, expired China/EU/Japan) are impacting sales.

Geographic Revenue Distribution (2025 Product Sales):

• US: $3.8 billion (52.6% of segment revenue)
• Emerging Markets: $1.8 billion (24.9% of segment revenue), with China contributing $0.8 billion.
• Europe: $1.7 billion (23.3% of segment revenue)
• Established ROW: $0.8 billion (11.0% of segment revenue), with Japan contributing $0.3 billion.

Vaccines & Immune Therapies

Financial Performance (2025 Product Sales):

• Revenue: $0.8 billion (-20.0% YoY actual, -19.0% YoY constant currency)
• Key Growth Drivers: Beyfortus sales declined in the US (-21%) but grew in Europe (+12%). FluMist sales were stable in the US but declined in Europe. Synagis sales declined in Europe (-56%) but grew in Emerging Markets (+2%).

Product Portfolio:

• Major product lines include Beyfortus (nirsevimab), FluMist (live attenuated influenza vaccine), and Synagis.
• New product launches or major updates: The pipeline includes AZD0292 (pseudomonas Psl-PcrV bispecific mAb for bronchiectasis) and AZD5148 (anti-clostridioides difficile TcdB mAb).

Market Dynamics:

• This segment is influenced by seasonal demand, public health initiatives, and competition from other vaccine manufacturers.
• Patent expiries for FluMist (US/China/EU/Japan 2025) and Beyfortus (US 2028) are relevant.

Geographic Revenue Distribution (2025 Product Sales):

• Emerging Markets: $0.2 billion (27.5% of segment revenue)
• US: $0.2 billion (25.9% of segment revenue)
• Europe: $0.4 billion (43.8% of segment revenue)
• Established ROW: $0.1 billion (7.8% of segment revenue)

Rare Disease

Financial Performance (2025 Product Sales):

• Revenue: $8.1 billion (+5.2% YoY actual, +7.0% YoY constant currency)
• Key Growth Drivers: Strong growth from Ultomiris (+18% US, +84% Emerging Markets, +19% Europe, +16% Established ROW) and Strensiq (+14% US, +94% Emerging Markets, +25% Europe, +23% Established ROW). Soliris experienced significant declines (-28% US, -9% Emerging Markets, -52% Europe, -32% Established ROW) due to competition and transition to Ultomiris. Koselugo also showed growth across regions.

Product Portfolio:

• Major product lines include Ultomiris (ravulizumab), Soliris (eculizumab), Strensiq (asfotase alfa), and Koselugo (selumetinib).
• New product launches or major updates: The pipeline includes anselamimab (fibril-reactive mAb for amyloid light-chain amyloidosis), cliramitug (transthyretin depleter for transthyretin amyloid cardiomyopathy), and gefurulimab (novel anti-C5 nanobody for generalised myasthenia gravis).

Market Dynamics:

• The rare disease market is characterized by high unmet medical needs, premium pricing, and specialized patient populations. Competition often involves next-generation therapies and biosimilars for established products.
• Patent expiries for Soliris (US 2027, China/EU 2029) are driving the shift to Ultomiris, which has later expiries (US 2035, China/EU 2035).

Geographic Revenue Distribution (2025 Product Sales):

• US: $5.4 billion (66.9% of segment revenue)
• Europe: $1.6 billion (19.8% of segment revenue)
• Established ROW: $1.1 billion (13.1% of segment revenue), with Japan contributing $0.8 billion.
• Emerging Markets: $1.0 billion (12.8% of segment revenue)

International Operations & Geographic Analysis

Revenue by Geography (2025 Product Sales):

International Business Structure:

• Subsidiaries: AstraZeneca PLC operates through a vast network of wholly-owned subsidiaries globally, including Alexion Pharmaceuticals, Inc. (US), AstraZeneca K.K. (Japan), AstraZeneca do Brasil Limitada (Brazil), AstraZeneca Pharmaceutical Co., Ltd. (China), and AstraZeneca UK Limited (UK). It also has subsidiaries with less than 100% interest, such as AstraZeneca Algeria Pharmaceutical Industries SPA (49%) and AstraZeneca Pharma India Limited (75%).
• Joint Ventures: The Company participates in joint ventures, including IHP HK Holdings Limited (50%, in liquidation) in Hong Kong and Montrose Chemical Corporation of California (50%) in the United States.
• Licensing Agreements: While not explicitly detailed as separate agreements, the acquisition of FibroGen China in 2025 included gaining control of roxadustat rights and manufacturing in China, indicating strategic licensing or rights acquisition as part of its international expansion.

Cross-Border Trade:

• Export Markets: The Company's global sales distribution indicates extensive export activities across its therapeutic areas, with products manufactured in various regions and distributed worldwide.
• Import Dependencies: Not explicitly detailed in the filing.
• Transfer Pricing: AstraZeneca PLC manages worldwide transfer pricing exposures, with a net tax liability of $120 million in 2025, indicating active inter-company transactions and associated tax planning.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: AstraZeneca PLC has not repurchased any Ordinary Shares since 2012.
• Dividend Payments: $4.8 billion (2025)
• Dividend Yield: Not disclosed.
• Future Capital Return Commitments: Dividends declared and paid in 2025 included a second interim dividend of $2.10 per share and a first interim dividend of $1.03 per share.

Balance Sheet Position (at December 31, 2025):

• Cash and Equivalents: $5.7 billion
• Total Debt: $27.8 billion
• Net Cash Position: $(22.1) billion (Net Debt)
• Credit Rating: P-1 (Moody’s) and A-1 (Standard and Poor’s) for short-term; A1 (Moody’s) and A+ (Standard and Poor’s) for long-term.
• Debt Maturity Profile (undiscounted, at December 31, 2025): $26.3 billion due within one year, $4.9 billion in one to two years, $4.1 billion in two to three years, $5.0 billion in three to four years, $3.8 billion in four to five years, and $20.5 billion in more than five years.

Cash Flow Generation (2025):

• Operating Cash Flow: $14.6 billion
• Free Cash Flow: Not explicitly stated or calculable from provided data without specific capital expenditure figures.
• Cash Conversion Metrics: Not explicitly detailed.

Currency Management:

• Cash holdings by major currencies: Not explicitly detailed, but the Company's functional currency is US dollars, and it manages significant non-US dollar revenue and cost exposures.
• Natural hedging through operational diversification: Not explicitly detailed.
• Financial hedging instruments and strategies: The Company utilizes cross-currency swaps and forward foreign exchange contracts to manage currency risk, including net investment hedges, cash flow hedges, and fair value hedges. External dividend payments in pound sterling and Swedish krona are fully hedged from announcement to payment date.

Operational Excellence

Information regarding production & service model, global supply chain architecture, key suppliers & partners, facility network, and specific operational metrics is not explicitly detailed in the provided filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Not explicitly detailed, but implied through regional sales forces.
• Channel Partners: In the US, sales are significantly concentrated with three wholesalers, accounting for approximately 78% of US sales in 2025. In Iran, products are exclusively sold by a third-party distributor.
• Digital Platforms: Not explicitly detailed.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: The high concentration of US sales with three wholesalers indicates significant relationships with major pharmaceutical distributors.
• Strategic Partnerships: Not explicitly detailed in terms of customer relationships, but acquisitions like Gracell and Fusion indicate strategic collaborations for pipeline development.
• Customer Concentration: US sales to three wholesalers accounted for approximately 78% of US sales in 2025, indicating a notable concentration risk within the US market.

Regional Market Penetration:

• US: $23.4 billion in product sales in 2025, representing 42.2% of total product sales.
• Emerging Markets: $15.1 billion in product sales in 2025, representing 27.1% of total product sales, with China contributing $6.6 billion (44% of Emerging Markets sales).
• Europe: $12.0 billion in product sales in 2025, representing 21.6% of total product sales.
• Established ROW: $5.1 billion in product sales in 2025, representing 9.1% of total product sales, with Japan contributing $3.6 billion (71% of Established ROW sales).

Competitive Intelligence

Global Market Structure & Dynamics

Industry Characteristics: AstraZeneca PLC operates in the global pharmaceutical industry, characterized by intensive research and development, stringent regulatory requirements, and a focus on innovation in therapeutic areas such as oncology, CVRM, respiratory & immunology, vaccines & immune therapies, and rare diseases. The market is dynamic, influenced by product pipeline success, pricing pressures, and the competitive environment.

Competitive Positioning Matrix: Information for a detailed competitive positioning matrix is not explicitly provided in the filing.

Direct Competitors

Specific direct competitors are not explicitly named in the filing.

Regional Competitive Dynamics: Variations in competitive landscape by major geographic markets are not explicitly detailed in the filing.

Risk Assessment Framework

Strategic & Market Risks

Global Market Dynamics: Risks include deterioration of pricing, affordability, access, and the competitive environment across various markets. Geopolitical and macroeconomic volatility also pose risks to strategic plans and targets. Technology Disruption: Failure or delay in pipeline delivery, development of new products, or meeting regulatory/ethical requirements. Risks associated with collecting and managing data and AI in line with ethical/regulatory requirements. Customer Concentration: High concentration of US sales with a few wholesalers presents a risk. Geographic diversification of sales across US, Emerging Markets, Europe, and Established ROW helps mitigate this.

Operational & Execution Risks

Global Supply Chain Vulnerabilities: Failure to maintain supply of compliant, quality products and general supply chain difficulties. Regional Disruptions: Unexpected events beyond control, including political, economic, and natural disaster risks, can impact operations. Trade Restrictions: Not explicitly detailed, but trade restrictions, tariffs, and export controls could impact global operations. Cybersecurity: Failure in information technology or cybersecurity, though the Company employs a multi-layered protection system consistent with NIST Cybersecurity Framework and has not experienced material incidents.

Financial & Regulatory Risks

Currency & Financial Risks: Geopolitical/macroeconomic volatility and foreign exchange rate movements pose significant risks, given approximately 59% of 2025 revenue was non-US dollar denominated. Failure to achieve strategic plans/targets and unexpected deterioration in financial position are also risks. Regulatory & Compliance Risks: Safety and efficacy concerns, adverse outcomes of litigation/government investigations, and intellectual property risks. Multi-jurisdictional compliance is complex, as evidenced by various legal proceedings and government investigations across regions (e.g., US, China, Brazil). Tax Regulations: Risks related to international tax planning, transfer pricing exposures ($120 million net tax liability in 2025), and compliance with new regulations like Pillar Two income tax ($194 million charge in 2025).

Geopolitical & External Risks

Country-Specific Risks: Operations in various countries expose the Company to political and economic instability, currency devaluation, and local regulatory changes. For example, the Company has a legal entity and sales activities in Iran, which carries specific geopolitical and compliance risks, though deemed immaterial to overall operations.

Innovation & Technology Leadership

Research & Development Focus: Global R&D Network: AstraZeneca PLC maintains a robust global R&D network, with significant R&D centers in China (e.g., AstraZeneca Global R&D (Beijing) Co., Ltd., AstraZeneca Rare Disease R&D (Beijing) Co., Ltd.) and the US (e.g., MedImmune, LLC). Sharon Barr leads BioPharmaceuticals R&D, and Susan Galbraith leads Oncology Haematology R&D, both with extensive experience in drug development. Innovation Pipeline: The Company has an extensive development pipeline as of February 10, 2026, spanning Phase I, II, and III across Oncology, CVRM, Respiratory & Immunology, Vaccines & Immune Therapies, and Rare Disease. Key areas of focus include CAR-T therapies (AZD0120), ADCs (AZD0516, AZD4360, AZD4512, AZD0305, puxitatug samrotecan, sonesitatug vedotin, tilatamig samrotecan, torvutatug samrotecan, Datroway, Enhertu), radioconjugates (AZD2068, AZD2284, FPI-2265), and bispecific antibodies (AZD5863, AZD6621, AZD5492, surovatamig, volrustomig, rilvegostomig).

Intellectual Property Portfolio:

• Patent Strategy: AstraZeneca PLC actively manages a global patent portfolio to protect its key marketed products. Patent expiry dates are critical for product lifecycle management, with significant expiries for products like Brilinta/Brilique (US/EU 2025), FluMist (US/China/EU/Japan 2025), Symbicort (US 2025), Farxiga/Forxiga (US 2026), Calquence (US 2026), and Soliris (US 2027). The Company is involved in various patent litigation cases both defending against challenges (e.g., Enhertu, Forxiga, Soliris, Tagrisso) and enforcing its patents (e.g., Brilinta, Calquence, Farxiga, Lynparza, Tagrisso).
• Licensing Programs: Not explicitly detailed as revenue-generating licensing programs, but the Company engages in in-licensing activities as part of its R&D strategy, with future potential milestone payments for research and development totaling $10.2 billion and for revenue totaling $21.3 billion.
• IP Litigation: The Company is involved in multi-jurisdictional IP litigation, including cases in the US, Europe, China, and Canada, reflecting the global nature of its patent protection efforts.

Technology Partnerships:

• Strategic Alliances: Acquisitions like Gracell Biotechnologies Inc. and Fusion Pharmaceuticals Inc. represent strategic alliances to integrate advanced cell therapy and radioconjugate technologies into AstraZeneca PLC's pipeline.
• Research Collaborations: Not explicitly detailed, but implied through its extensive R&D activities and pipeline development.

Leadership & Governance

Executive Leadership Team (as at February 10, 2026)

International Management Structure: The Executive Leadership Team includes an Executive Vice-President, International (Iskra Reic), responsible for strategy and sustainable growth across the International region, encompassing China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand. This structure highlights a dedicated focus on managing and expanding operations across diverse global markets.

Board Composition: The Company's corporate governance differs from NYSE standards in several areas. The appointment of external auditors is by shareholders, not solely the audit committee. Nominating/Corporate Governance and Compensation Committees are required to have a majority of independent members (UK Code) rather than solely independent directors (NYSE). Shareholder approval is required for equity compensation plans under FCA Rules, not necessarily all material plans. As a foreign private issuer, the CEO is not required to provide annual certification of compliance with NYSE corporate governance listing standards. The Board of Directors’ Audit Committee provides oversight of cybersecurity risks.

Regulatory Environment & Compliance

Multi-Jurisdictional Regulatory Framework: Primary Regulatory Environments: AstraZeneca PLC operates under the regulatory frameworks of numerous jurisdictions, including the UK (domicile), US (significant market and listing), Europe, China, and Japan, which are key markets for its product sales and R&D activities. Compliance requirements vary significantly by region, impacting product development, approval, manufacturing, and commercialization. Cross-Border Compliance:

• Export Controls: Not explicitly detailed.
• Sanctions Compliance: The Company maintains a legal entity in Iran, AstraZeneca Pars Company, and conducts limited sales activities through a third-party distributor. This operation is subject to US and international sanctions regulations, though deemed immaterial to AstraZeneca PLC's overall business.
• Anti-Corruption: Not explicitly detailed, but implied through general compliance requirements in its global operations.

International Tax Strategy:

• Transfer Pricing: The Company manages significant worldwide transfer pricing exposures, with a net tax liability of $120 million in 2025, indicating complex inter-company transactions and associated tax compliance requirements across jurisdictions.
• Tax Treaties: Not explicitly detailed.
• BEPS Compliance: The Company recorded a Pillar Two income tax charge of $194 million in 2025, reflecting its compliance with global Base Erosion and Profit Shifting (BEPS) regulations.

Environmental & Social Impact

Global Sustainability Strategy: AstraZeneca PLC has a global sustainability strategy, with the Executive Vice-President, Global Operations, IT & Chief Sustainability Officer (Pam Cheng) responsible for its implementation. The Company assesses its maturity against the US National Institute of Standards and Technology (NIST) Cybersecurity Framework (CSF) and reviews cybersecurity operations and performance metrics, which are summarized in enterprise risk reporting to the Senior Executive Team (SET) and Audit Committee. Environmental Commitments: Not explicitly detailed in terms of specific climate strategy, carbon neutrality, or renewable energy targets in the provided filing. Regional Sustainability Initiatives: Not explicitly detailed. Social Impact by Region: Not explicitly detailed.

Currency Management & Financial Strategy

Multi-Currency Operations: Currency Exposure (2025):

Hedging Strategies:

• Transaction Hedging: The Company uses forward foreign exchange contracts for short-term foreign exchange risk management.
• Translation Hedging: Cross-currency swaps are designated as net investment hedges to manage balance sheet currency exposure related to foreign investments (e.g., JPY, CNY, GBP, EUR investments).
• Economic Hedging: Not explicitly detailed as a distinct strategy, but the comprehensive hedging program aims to mitigate long-term competitive exposure from currency fluctuations.
• Financial hedging instruments include cross-currency interest rate swaps and forward foreign exchange contracts. All derivatives are held at fair value within Level 2 of the fair value hierarchy. External dividend payments in pound sterling and Swedish krona are fully hedged from announcement to payment date.